Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)

Condition:   Asthma
Interventions:   Drug: MK-1029 150 mg;   Drug: Placebo for MK-1029;   Drug: Montelukast 10 mg;   Drug: Albuterol/Salbutamol 90 mcg – 100 mcg per inhalation
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting – verified March 2016

View full post on ClinicalTrials.gov: asthma | received in the last 14 days